Cory Abate-Shen

Cory Abate-Shen

Titles

Michael and Stella Chernow Professor of Urological Oncology
Interim Director, Herbert Irving Comprehensive Cancer Center

Affiliations

Department of Pathology and Cell Biology
Department of Systems Biology
Center for Cancer Systems Therapeutics

Administrative Coordinator:
Rachel Kelly
rjk2135@cumc.columbia.edu


Cory Abate-Shen is a professor in the Department of Urology and Department of Pathology and Cell Biology, the Michael and Stella Chernow Chair of Urological Oncology, and an associate director of the Herbert Irving Cancer Center. She is investigating the molecular mechanisms of homeobox genes in development and cancer. Her laboratory has provided groundbreaking insights on the molecular bases of how homeoproteins achieve target gene recognition in vivo. She has also developed mouse models of prostate cancer that have been widely used to investigate the molecular bases of prostate tumorigenesis and as preclinical models for intervention and therapy. She has been the recipient of several awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and the Women in Cell Biology Junior Award from the American Society for Cell Biology. She is currently the principal investigator on five federal grants including an NCI consortium grant on Mouse Models of Human Cancer. In addition, she has received funding from several other sources including the March of Dimes, the New Jersey Commission on Cancer Research and the Gustave and Louise Pfeiffer Research Foundation. She has recently been named an American Association of Cancer Research Professor.

More News

News

Columbia Awarded NCI Center for Cancer Systems Biology
The Center for Cancer Systems Therapeutics (CaST) is developing a framework that can account for the dynamic nature of cancer and use this knowledge to disrupt the programs that maintain tumor survival.
Synergy between Two Genes Drives Aggressive Prostate Cancer
Using a new computational method for comparing regulatory networks in human cancer cells with those in a mouse model, researchers found that FOXM1 and CENPF together drive the most lethal prostate tumors.
Biomarker Identified for Predicting Prostate Cancer Aggressiveness
Measurements of the expression levels of three genes associated with aging can be used to better assess which patients with indolent prostate cancer require treatment.
Study Supports Cell-of-Origin Model of Prostate Cancer Heterogeneity
The cell-of-origin model suggests that the aggressiveness of a tumor may result from the type of cell from which it arises. A new study has identified molecular signatures that hold potential as biomarkers of specific prostate cancer subtypes.